You seem to be worried about this calcium problem too. It does seem to be an issue. Hmmmmm.
I think we just focus on making sure the humans in the upcoming phase 1 trial REALLY like cheese. That worked for the mice. So we already know that NYR is valued at $45billion for TBI, $52billion for stroke, $244b for hypertension, and also $442b for toenails now, already proven.
If we have to factor out lactose intolerant people from treatment, we are only left with a market cap north of $35 trillion dollars. Does that impact your forecasts?
NYR Price at posting:
11.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)